Sparks commentary

Healthcare

Sparks

Kuros Biosciences (SWX: KURN) surges on raised guidance
Published by Finlay Mathers

Kuros Biosciences raised its 2025 sales guidance to at least 70% growth after reporting a 77% revenue surge to US$101.1m for the first nine months of 2025. The Swiss medical device company’s Direct MagnetOs sales jumped 76% to US$99.7m, driven by strong demand for its bone graft technology. Kuros reported EBITDA of US$7.4m, up from US$1.6m a year earlier, delivering a 12.1% adjusted EBITDA margin. The company launched its MagnetOs MIS Delivery System in the US following FDA clearance and secured Saudi Food and Drug Authority approval for MagnetOs Putty and Granules.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free